Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 4:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Radiotracer Clear all
Completed Early Phase 1 Interventional Accepts healthy volunteers

[C-11]NOP-1A and Alcohol Use Disorder

NCT03448016
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
[C-11], NOP-1A
Radiation · Drug
Lead sponsor
Rajesh Narendran
Other
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2022 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Locus-coeruleus Function in Normal Elderly and AD Risk

NCT04403165
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Nocturnal polysomnography (NPSG), Lumbar Puncture (LP), PET-MR measurement with a norepinephrine transporter (NET)-selective radiotracer (S,S)-[11C]Omethylreboxetine ([11C]MRB), Psychomotor Vigilance Task (PVT)
Procedure · Other · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
55 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Not applicable Interventional Results available

Patterns and Prevalence of FDG Extravasation in PET/CT Scans

NCT03041090
View directory record Official record
Conditions
Intravenous Infiltration
Interventions
Lucerno ID (identification) System
Device
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 90 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

NCT00375830
View directory record Official record
Conditions
Cancer
Interventions
Bone scan, 99mTc-methyl diphosphonate, Positron Emission Tomography (PET) scan, 18F-Fludeoxyglucose (18F-FDG), Computed Tomography (CT) scan, 18F-Sodium Fluoride (18F-NaF), Whole Body Magnetic Resonance Imaging (WB-MRI) scan, Gadopentetate dimeglumine, Gadofosveset, Gadobutrol
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 23, 2026, 4:59 PM EDT
Recruiting Phase 1 Interventional

Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)

NCT07559500
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
Tirzepatide, Placebo, [11C]raclopride plus drug, [11C]NNC-112
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 23, 2026, 4:59 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Linking Cognitive Functioning to Multimodal Imaging in Multiple Sclerosis (MS)

NCT03723356
View directory record Official record
Conditions
Multiple Sclerosis, Cognition Disorders
Interventions
Siemens Biograph mMR (molecular MR), fMRI, Diffusion Spectrum Imaging (DSI)
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Not applicable Interventional

Impact of Osteopathic Manipulative Medicine on Sentinal Lymph Node Biopsy Dye and Tracer Uptake

NCT07269860
View directory record Official record
Conditions
Breast Cancer
Interventions
OMM prior to SLNB
Procedure
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 23, 2026, 4:59 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease

NCT03622359
View directory record Official record
Conditions
Peripheral Artery Disease, Diabetes Mellitus, Chronic Limb-Threatening Ischemia
Interventions
SPECT/CT perfusion imaging, PET/CT perfusion imaging
Diagnostic Test
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 23, 2026, 4:59 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH

NCT03332940
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, NASH - Nonalcoholic Steatohepatitis
Interventions
Tc 99M Sulfur Colloid, Tc99m-tilmanocept
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 23, 2024 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Plasma P-tau2017 and Quantitative Amyloid PET Imaging

NCT05164536
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Amyvid
Drug
Lead sponsor
Invicro
Other
Eligibility
70 Years and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Myocardial Perfusion Imaging Galmydar Rest/Stress

NCT05625490
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ga-68 Galmydar, 13N-ammonia
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine

NCT00800956
View directory record Official record
Conditions
Healthy
Interventions
[14C]-esreboxetine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years to 65 Years · Male only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Apr 6, 2011 · Synced Sep 23, 2026, 4:59 PM EDT
Withdrawn Early Phase 1 Interventional

Dopamine Rhythms in Health and Addiction

NCT02233829
View directory record Official record
Conditions
Cocaine Abuse
Interventions
Brain Dopamine Reactivity, Brain Dopamine Receptor
Drug · Radiation
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 23, 2026, 4:59 PM EDT
Recruiting Early Phase 1 Interventional

[C-11]NPA PET-amphetamine in Cocaine Use Disorders

NCT05011760
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Baseline [C-11]NPA PET Scan, d-amphetamine, Post-amphetamine [C-11]NPA PET Scan
Radiation · Drug
Lead sponsor
Rajesh Narendran
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 23, 2026, 4:59 PM EDT
Withdrawn Phase 3 Interventional

68Ga Citrate PET/MRI for Evaluation of Fever of Unknown Origin (FUO)

NCT04139395
View directory record Official record
Conditions
Fever of Unknown Origin
Interventions
68Ga-Citrate PET/MRI, 67Ga-Citrate SPECT, Positron Emission Tomography, Magnetic Resonance Imaging, SPECT
Drug · Device
Lead sponsor
Carina Mari Aparici
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 23, 2026, 4:59 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

PennPET Explorer Scanner Evaluation

NCT04617912
View directory record Official record
Conditions
Healthy, Cognitive Impairment
Interventions
Long AFOV PennPET Explorer
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Determining Lipid Content in Stool After Alpha-cyclodextrin

NCT03002168
View directory record Official record
Conditions
Healthy Participants
Interventions
Alpha-cyclodextrin, Placebo, Triolein radiolabeled with 100 microcuries of 3^Hydrogen, Tripalmitin radiolabeled with 20 microcuries of 14^Carbon
Dietary Supplement · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 23, 2026, 4:59 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

A Study of the Pharmacokinetics, Biodistribution and Dosimetry of Granzyme-B Targeted [Cu-64]-Labeled PET Radiotracers in Adult Healthy Volunteers

NCT07774650
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Granzyme-B targeted [64Cu]-labeled PET radiotracer
Drug
Lead sponsor
Ratio Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 23, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers

NCT02602860
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[11C]UCB-J, Brivaracetam, Levetiracetam
Radiation · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 29, 2017 · Synced Sep 23, 2026, 4:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Examination of Glutamate and mGluR5 in Psychiatric Disorders

NCT02727972
View directory record Official record
Conditions
Major Depressive Disorder, Post-Traumatic Stress Disorder, Bipolar Disorder
Interventions
Cognitive Testing, MRI, PET
Behavioral · Other · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 23, 2026, 4:59 PM EDT
Terminated Early Phase 1 Interventional Results available

Imaging Study for FdCyd and THU Cancer Treatment

NCT01479348
View directory record Official record
Conditions
Head and Neck Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms
Interventions
[F-18]-5-FLUORO-2'-DEOXYCYTIDINE, Tetrahydrouridine intravenous (IV), Tetrahydrouridine (oral), Positron emission tomography (PET)/Computed tomography (CT)
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Sep 23, 2026, 4:59 PM EDT
Recruiting Phase 1 Interventional

Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)

NCT06160284
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Yale University
Other
Eligibility
25 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 23, 2026, 4:59 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Imaging SV2A in Mood Disorders

NCT02734602
View directory record Official record
Conditions
Major Depressive Disorder, Post-Traumatic Stress Disorder
Interventions
Ketamine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 23, 2026, 4:59 PM EDT
Active, not recruiting Early Phase 1 Interventional

18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma

NCT03541720
View directory record Official record
Conditions
Neuroblastoma, Pheochromocytoma
Interventions
18F-DA
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 23, 2026, 4:59 PM EDT